Akebia Therapeutics announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending the European Commission to approve Vafseo, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of symptomatic anaemia associated with chronic kidney disease in adults on chronic maintenance dialysis. The EC will review the CHMP recommendation and deliver a final decision in approximately two months. The decision will be applicable to all 27 European Union member states plus Iceland, Norway and Liechtenstein.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on AKBA: